Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 279-285

  Becker, Nikolaus ^a   Byl, Anne ^a   Friedrich, Susanne ^a   Jauch, Anna ^b   Schnitzler, Paul ^b   Egerer, Gerlinde ^b   Ho, Anthony D ^b   Goldschmidt, Hartmut ^a   Neben, Kai ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chromosomal aberrations; HBV; Lymphoma; Non Hodgkin lymphoma

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CASE CONTROL STUDY; CHROMOSOME 11Q23; CHROMOSOME 13Q14; CHROMOSOME 15Q22; CHROMOSOME 17P13; CHROMOSOME 19Q13; CHROMOSOME 1Q21; CHROMOSOME 6Q21; CHROMOSOME 8P; CHROMOSOME 8P21; CHROMOSOME 9P34; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q11; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GAIN OF FUNCTION MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; VIRUS STRAIN;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENETIC ASSOCIATION STUDIES; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; REGISTRIES; VIRUS INTEGRATION;

EID: 84875256919     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12018     Document Type: Article

References (29)

1. Franceschi S, Lise M, Trépo C, et al. Infection with Hepatitis B and C viruses and risk of lymphoid malignancies in the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomark Prev 2010;20:208-14.
2. Becker N, Schnitzler P, Boffetta B, Brennan P, Foretova L, Maynadié M, Nieters A, Staines A, Cocco P, de Sanjosé S. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study EPILYMPH. J Cancer Res Clin Oncol 2012 (in press).
3. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000;174:98-111.
4. Nishida N, Nishimura T, Ito T, Komeda T, Fukuda Y, Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003;18:897-909.
5. Tsai W-L, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;16:2309-24.
6. Sy SM-H, Wong N, Lai PB-S, To K-F, Johnson PJ. Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod Pathol 2005;18:686-92.
7. Moinzadeh P, Breuhahn K, Stützer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-41.
8. Özkal P, Ilgin-Ruhi H, Akdoǧan M, Halil Elhan A, Kaçar S, Şaşmaz N. The genotoxic effects of hepatitis B virus to host DNA. Mutagenesis 2005;20:147-50.
9. Bhargava A, Khan S, Panwar H, Pathak N, Punde RP, Varshney S, Mishra PK. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res 2010;153:143-50.
10. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Groupe Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-38.
11. Liebisch P, Scheck D, Erné SA, et al. Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Genes Chromosom Cancer 2005;42:78-81.
12. Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, Hose D, Ho AD, Goldschmidt H, Neben K. Chromosomal Aberrations +1q21 and del(17p13) predict survival in patients with recurrent Multiple Myeloma treated with Lenalidomide and Dexamethasone. Cancer 2010;117:2136-44.
13. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in Multiple Myeloma patients with deletion 17p. Blood 2012;119:940-8.
14. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Fran- cophone du Myelome. Blood 2007;109:3489-95.
15. Gutiérrez NC, Castellanos MV, Martín ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myelo- ma undergoing autologous stem cell trans- plantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-50.
16. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients′ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
17. Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004;72:203-14.
18. Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. The prognostic significance of 8p21 deletion in multiple myeloma. Br J Haematol 2008;144:263-75.
19. Martinez-Climent JA, Viscarra E, Sanchez D, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001;98:3479-82.
20. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005;106:3214-22.
21. Shetty OA, Naresh KN, Banavali SD, Shet T, Joshi R, Qureshi S, Mulherkar R, Borges A, Desai SB. Evidence for the presence of high risk human papillomavirus in retinoblastoma tissue from nonfamilial retinoblastoma in developing countries. Pediatr Blood Cancer 2012;58:185-90.
22. Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G. Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med 2011;269:137-47.
23. Zhang Y, Gostissa M, Hildebrand DG, Becker MS, Boboila C, Chirale R, Lewis S, Alt FW. The Role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol 2010;106:93-133.
24. Küppers R. Mechanisms of B-CLL lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-62.
25. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006;25:3823-33.
26. de Sanjosé S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 2008;6:451-8.
27. Raimondo G, Allain J-P, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
28. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain J-P, Gerlich W. Nucleic acid testing to detect HBV Infection in blood donors. N Engl J Med 2011;364:236-47.
29. Minuk GY, Sun D-F, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette A, Martin B, Giulivi A. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005;42:480-5.